Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 21;14(10):2535.
doi: 10.3390/cancers14102535.

DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer

Shuhei Hirano  1 , Kazumasa Matsumoto  1 , Kei Tanaka  2   3 , Noriyuki Amano  1 , Dai Koguchi  1 , Masaomi Ikeda  1 , Yuriko Shimizu  1 , Benio Tsuchiya  2 , Ryo Nagashio  2 , Yuichi Sato  1   2 , Masatsugu Iwamura  1
Affiliations

DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer

Shuhei Hirano et al. Cancers (Basel). .

Abstract

The overexpression of DJ-1 protein and its secretion into the bloodstream has been reported in various neoplasms. However, serum levels and the subcellular localization of DJ-1 have not been analyzed in detail in bladder cancer (BC). Our comprehensive analysis of these variables started with the measurement of DJ-1 in serum from 172 patients with BC, 20 patients with urolithiasis and 100 healthy participants. Next, an immunohistochemical study of DJ-1 expression and localization was conducted in 92 patients with BC, and associations with clinicopathologic factors and patient outcomes were evaluated. Serum DJ-1 was significantly higher in patients with BC than in those with urolithiasis or in healthy participants. Immunohistochemically, a cytoplasm-positive (Cy+) and nucleus-negative (N-) DJ-1 pattern was associated with age and pathologic stage. Log-rank tests indicated that the Cy+, N- pattern was significantly associated with overall survival (OS), recurrence-free survival (RFS), and cancer specific survival (CSS). In addition, the Cy+, N- pattern was an independent prognostic factor in the multivariate analysis adjusted for the effects of the clinicopathologic outcomes. The investigation of DJ-1 expression might help physicians to make decisions regarding further follow-up and additional treatments.

Keywords: DJ-1; bladder cancer; cystectomy; serum; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Serum concentrations of DJ-1 protein by reverse-phase protein array analysis (A) in patients with bladder cancer or urolithiasis and in healthy participants, and (B) in patients with non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Figure 2
Figure 2
Receiver operating characteristic analysis of preoperative serum concentrations of DJ-1 for the detection of bladder cancer in (A) patients with bladder cancer compared with healthy participants, (B) patients with bladder cancer compared with patients with urolithiasis, and (C) patients with Ta/1 bladder cancer compared with healthy participants. AUC = area under the curve.
Figure 3
Figure 3
DJ-1 expression patterns in non-neoplastic urothelial cells and urothelial carcinoma. (A) Nuclear staining observed in non-neoplastic urothelial cells. (B) Cytoplasm-positive, nucleus-negative: Group 1. (C) Cytoplasm-positive, nucleus-positive: Group 2. (D) Cytoplasm-negative, nucleus-positive: Group 3. (E) Cytoplasm-negative, nucleus-negative: Group 4. All 400× original magnification.
Figure 4
Figure 4
Probability of (A) overall survival and (B) cancer-specific survival after radical cystectomy by DJ-1 expression group. Group 1—cytoplasm-positive, nucleus-negative; Group 2—cytoplasm-positive, nucleus-positive; Group 3—cytoplasm-negative, nucleus-positive; Group 4—cytoplasm-negative, nucleus-negative.
Figure 5
Figure 5
Probability of (A) overall survival, (B) recurrence-free survival, and (C) cancer-specific survival after radical cystectomy for Group 1 and Group 2–4. Group 1—cytoplasm-positive, nucleus-negative; Group 2—cytoplasm-positive, nucleus-positive; Group 3—cytoplasm-negative, nucleus-positive; Group 4—cytoplasm-negative, nucleus-negative.
See this image and copyright information in PMC

References

    1. Fitzmaurice C., Abate D., Abbasi N., Abbastabar H., Abd-Allah F., Abdel-Rahman O., Abdelalim A., Abdoli A., Abdollahpour I., Abdulle A.S.M., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749–1768. doi: 10.1001/jamaoncol.2019.2996. - DOI - PMC - PubMed
    1. Cambier S., Sylvester R.J., Collette L., Gontero P., Brausi M.A., van Andel G., Kirkels W.J., Silva F.C., Oosterlinck W., Prescott S., et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guerin. Eur. Urol. 2016;69:60–69. doi: 10.1016/j.eururo.2015.06.045. - DOI - PubMed
    1. Nakamura K., Kasraeian A., Iczkowski K.A., Chang M., Pendleton J., Anai S., Rosser C.J. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol. 2009;9:12. doi: 10.1186/1471-2490-9-12. - DOI - PMC - PubMed
    1. Van der Aa M.N., Steyerberg E.W., Sen E.F., Zwarthoff E.C., Kirkels W.J., van der Kwast T.H., Essink-Bot M.L. Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: A randomized comparison. BJU Int. 2008;101:1106–1110. doi: 10.1111/j.1464-410X.2007.07224.x. - DOI - PubMed
    1. Mowatt G., Zhu S., Kilonzo M., Boachie C., Fraser C., Griffiths T.R.L., N’Dow J., Nabi G., Cook J., Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol. Assess. 2010;14:1–331. doi: 10.3310/hta14040. - DOI - PubMed

LinkOut - more resources